Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Lipella Pharmaceuticals Inc. (LIPO)
USD0.06
0.00 (-6.49%)
US OTC Healthcare Biotechnology
Address
7800 Susquehanna St. 15208
Pittsburgh, PA, US
Pittsburgh, PA, US
CEO
Jonathan Kaufman
Website
lipella.com
IPO
2022-12-19
CIK 1347242 ISIN US53630L2097
Description
Lipella Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the creation of novel therapies. The company achieves this by repurposing and optimizing the active ingredients found in established generic drugs, tailoring these reformulations for diverse medical applications. Its lead candidate, LP-10, a tacrolimus formulation, is presently in Phase IIa clinical studies, targeting radiation-induced hemorrhagic cystitis. Additionally, LP-310, another tacrolimus-derived compound, is under development for the management of oral lichen planus. Founded in 2005, the company maintains its headquarters in Pittsburgh, Pennsylvania.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.06
0.00 (-6.49%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
36.8K
Beta
1.50
Float Shares
4.33M
Free Float %
93.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +100.00% | -37.50% | -69.70% | -44.44% | -96.40% | -99.32% | -98.26% | -98.26% | -98.26% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.06
Low
2.00
+2,996.0%
Consensus
2.00
+2,996.0%
Median
2.00
+2,996.0%
High
2.00
+2,996.0%
Ratings Trend (MoM)
100% Bullish
| Rating | 2025-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 1 |
2.00
+2,996.0%
|
Quality scores
Altman Z-Score
-17.91
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+19.3% ★
-
EPS growth Biotechnology: +29.7%+22.2% Q3'25: +78.3% (vs Q3'24)
-
FCF margin FCF growth · Biotechnology: +16.2%-913.6%
-
EBIT margin Biotechnology: +0.0%-935.3%
-
ROIC Biotechnology: -16.1%— Q3'25: +4,896.7% (vs Q3'24)
-
Share dilution Biotechnology: -3.4%+39.7% Q3'25: +306.5% (vs Q3'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.01× Q3'25: -0.05× (vs Q3'24)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
536.4K
est: 363.0K (+47.8%)
|
559.5K
est.
|
583.7K
583.7K – 583.7K
+4.3% YoY
|
608.9K
608.9K – 608.9K
+4.3% YoY
|
26.37M
26.37M – 26.37M
+4,231.0% YoY
|
46.84M
46.84M – 46.84M
+77.6% YoY
|
| EBITDA |
-5.01M
est: -294.5K (-1,602.6%)
|
-453.9K
est.
|
-473.4K
-473.4K – -473.4K
-4.3% YoY
|
-493.9K
-493.9K – -493.9K
-4.3% YoY
|
-21.39M
-21.39M – -21.39M
-4,231.0% YoY
|
-38.00M
-38.00M – -38.00M
-77.6% YoY
|
| EBIT |
-5.02M
est: -294.5K (-1,603.6%)
|
-453.9K
est.
|
-473.4K
-473.4K – -473.4K
-4.3% YoY
|
-493.9K
-493.9K – -493.9K
-4.3% YoY
|
-21.39M
-21.39M – -21.39M
-4,231.0% YoY
|
-38.00M
-38.00M – -38.00M
-77.6% YoY
|
| Net Income |
-5.02M
est: -8.23M (+39.0%)
|
-5.45M
est.
|
-18.26M
-18.26M – -18.26M
-235.0% YoY
|
-2.29M
-2.29M – -2.29M
+87.5% YoY
|
419.3K
419.3K – 419.3K
+118.3% YoY
|
2.65M
2.65M – 2.65M
+532.5% YoY
|
| SGA |
2.00M
est: 913.0K (+119.5%)
|
1.41M
est.
|
1.47M
1.47M – 1.47M
+4.3% YoY
|
1.53M
1.53M – 1.53M
+4.3% YoY
|
66.32M
66.32M – 66.32M
+4,231.0% YoY
|
117.80M
117.80M – 117.80M
+77.6% YoY
|
| EPS |
-4.79
est: -7.85 (+39.0%)
|
-5.20
est.
|
-17.42
-17.42 – -17.42
-235.0% YoY
|
-2.18
-2.18 – -2.18
+87.5% YoY
|
0.40
0.40 – 0.40
+118.3% YoY
|
2.53
2.53 – 2.53
+532.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-2.36B
OE per share TTM
-521.05
Owner's Yield
-519,182.22%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
26.4%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
7
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Alfonso J. Cervantes, Jr. | 9.39M | 29.19% | 3.00M | 6.39M | 3.00M | 6.39M | IN | — | 2022-03-21 | ↗ |
| 2 | Trilogy Capital Group LLC | 6.39M | 20.50% | — | 6.39M | — | 6.39M | PN | — | 2022-03-21 | ↗ |
| 3 | B. Chancellor | 1.68M | 16.00% | 1.68M | — | 1.68M | 11.00 | IN | — | 2024-10-17 | ↗ |
| 4 | Darren C. Minton | 1.60M | 5.09% | 1.60M | — | 1.60M | 11.00 | IN | — | 2022-03-21 | ↗ |
| 5 | H. Kaufman | 1.16M | 18.60% | 1.16M | — | 1.16M | 11.00 | IN | — | 2022-12-29 | ↗ |
| 6 | Leaf Huang | 555.6K | 9.70% | 555.6K | — | 555.6K | — | IN | United States | 2023-02-09 | ↗ |
| 7 | S | 353.3K | 5.80% | 353.3K | — | 353.3K | — | IN | United States | 2023-03-29 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
2.00
Bullish
Ratio by volume
2.16
Bullish
Buys
4
Sells
2
Shares acquired
681.4K
Shares disposed
314.8K
Cash buys
—
Cash sales
—
Net activity
+366,554
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-04-03 | Kaufman Jonathan H | Director / Officer / 10% Owner | J-Other | D | Series C Voting Convertible Preferred Stock | 536,959 | 1.00 | 537.0K | 0 | I | ↗ |
| 2025-03-13 | Kaufman Jonathan H | Director / Officer / 10% Owner | J-Other | A | Series C Voting Convertible Preferred Stock | 10,326 | 1.00 | 10.3K | 536,959 | I | ↗ |
| 2025-03-10 | Kaufman Jonathan H | Director / Officer / 10% Owner | J-Other | A | Series C Voting Convertible Preferred Stock | 84,700 | 1.00 | 84.7K | 526,633 | I | ↗ |
| 2025-02-28 | Kaufman Jonathan H | Director / Officer / 10% Owner | J-Other | A | Series C Voting Convertible Preferred Stock | 441,933 | 1.00 | 441.9K | 441,933 | I | ↗ |
| 2025-01-15 | Kaufman Jonathan H | Director / Officer / 10% Owner | J-Other | D | Common Stock Purchase Warrants | 11,795 | 1.00 | 11.8K | 0 | I | ↗ |
| 2024-12-31 | Kaufman Jonathan H | Director / Officer / 10% Owner | J-Other | A | Common Stock Purchase Warrants | 11,795 | 1.00 | 11.8K | 11,795 | I | ↗ |
| 2024-12-23 | Kaufman Jonathan H | Director / Officer / 10% Owner | J-Other | A | Series C Voting Convertible Preferred Stock | 260,108 | 1.00 | 260.1K | 260,108 | I | ↗ |
| 2024-05-14 | Kaufman Jonathan H | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 10,000 | 0.76 | 7.6K | 898,849 | — | ↗ |
| 2024-03-19 | Kaufman Jonathan H | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 25,000 | 0.87 | 21.8K | 888,849 | — | ↗ |
| 2024-03-18 | Kaufman Jonathan H | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 30,000 | 0.79 | 23.6K | 863,849 | — | ↗ |
| 2024-03-15 | Yoshimura Naoki | Director | A-Award | A | Stock Options | 25,000 | 0.77 | 19.3K | 25,000 | — | ↗ |
| 2024-03-15 | Pruchnic Ryan | Director | A-Award | A | Stock Options | 25,000 | 0.77 | 19.3K | 25,000 | — | ↗ |
| 2024-03-15 | Kim Byong | Director | A-Award | A | Stock Options | 25,000 | 0.77 | 19.3K | 25,000 | — | ↗ |
| 2024-03-15 | Kaufman Jonathan H | Director / Officer / 10% Owner | A-Award | A | Stock Options | 80,000 | 0.77 | 61.6K | 80,000 | — | ↗ |
| 2024-03-15 | Johnston Douglas | Officer | A-Award | A | Stock Options | 50,000 | 0.77 | 38.5K | 50,000 | — | ↗ |
| 2024-03-15 | Cohen Daniel R | Director | A-Award | A | Stock Options | 25,000 | 0.77 | 19.3K | 25,000 | — | ↗ |
| 2024-03-15 | Chancellor Michael B | Director / Officer / 10% Owner | A-Award | A | Stock Options | 80,000 | 0.77 | 61.6K | 80,000 | — | ↗ |
| 2024-03-15 | Birder Lori | Director | A-Award | A | Stock Options | 25,000 | 0.77 | 19.3K | 25,000 | — | ↗ |
| 2024-03-13 | Kaufman Jonathan H | Director / Officer / 10% Owner | A-Award | A | Common Stock | 144,906 | 0.69 | 100.0K | 833,849 | — | ↗ |
| 2024-03-13 | Chancellor Michael B | Director / Officer / 10% Owner | A-Award | A | Common Stock | 144,906 | 0.69 | 100.0K | 877,637 | — | ↗ |
| 2023-06-17 | Birder Lori | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-06-16 | Yoshimura Naoki | Director | A-Award | A | Stock Options | 25,000 | 2.19 | 54.8K | 25,000 | — | ↗ |
| 2023-06-16 | Pruchnic Ryan | Director | A-Award | A | Stock Options | 25,000 | 2.19 | 54.8K | 25,000 | — | ↗ |
| 2023-06-16 | Kim Byong | Director | A-Award | A | Stock Options | 25,000 | 2.19 | 54.8K | 25,000 | — | ↗ |
| 2023-06-16 | Kaufman Jonathan H | Director / Officer / 10% Owner | A-Award | A | Stock Options | 79,500 | 2.19 | 174.1K | 79,500 | — | ↗ |
| 2023-06-16 | Johnston Douglas | Officer | A-Award | A | Options to Purchase | 50,000 | 2.19 | 109.5K | 50,000 | — | ↗ |
| 2023-06-16 | Cohen Daniel R | Director | A-Award | A | Stock Options | 25,000 | 2.19 | 54.8K | 25,000 | — | ↗ |
| 2023-06-16 | Chancellor Michael B | Director / Officer / 10% Owner | A-Award | A | Stock Options | 79,500 | 2.19 | 174.1K | 79,500 | — | ↗ |
| 2023-06-16 | Battleman David S. | Director | A-Award | A | Stock Options | 25,000 | 2.19 | 54.8K | 25,000 | — | ↗ |
| 2023-03-21 | Cohen Daniel R | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-12-22 | Chancellor Michael B | Officer | J-Other | A | Common Stock | 22,950 | 5.75 | 132.0K | 732,730 | — | ↗ |
| 2022-12-19 | Kaufman Jonathan H | Officer | — | D | Common Stock | 0 | 0.00 | — | 688,941 | — | ↗ |
| 2022-12-19 | Johnston Douglas | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-12-19 | Chancellor Michael B | Officer | — | D | Common Stock | 0 | 0.00 | — | 709,780 | — | ↗ |
| 2022-02-22 | Kim Byong | Director | — | D | Stock Options | 10,000 | 5.00 | 50.0K | — | — | ↗ |
| 2021-09-03 | Yoshimura Naoki | Director | — | D | Stock Options | 10,000 | 5.00 | 50.0K | — | — | ↗ |
| 2021-09-03 | Pruchnic Ryan | Director | — | D | Stock Options | 10,000 | 5.00 | 50.0K | — | — | ↗ |
| 2021-09-03 | Battleman David S. | Director | — | D | Stock Options | 10,000 | 5.00 | 50.0K | — | — | ↗ |
Executive team
Top executives
EBIT / Employee
-10.0K
Shares Outstanding
4.62M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2023 | Jonathan Kaufman, Chief Executive Officer | 204.1K | — | — | 119.3K | — | — | 323.4K | 36.88% | ↗ |
| 2 | 2023 | Michael Chancellor, Chief Medical Officer | 195.8K | — | — | 119.3K | — | — | 315.1K | 37.85% | ↗ |
| 3 | 2023 | Douglas Johnston, Chief Financial Officer | 165.0K | 20.0K | — | 75.0K | — | — | 260.0K | 28.85% | ↗ |
| 4 | 2022 | Jonathan Kaufman, Chief Executive Officer | 183.3K | — | — | 730.5K | — | — | 913.8K | 79.94% | ↗ |
| 5 | 2022 | Michael Chancellor, Chief Medical Officer | 175.0K | — | — | 730.5K | — | — | 905.5K | 80.67% | ↗ |
| 6 | 2022 | Douglas Johnston, Chief Financial Officer | 67.5K | — | — | — | — | — | 67.5K | 0.00% | ↗ |
| 7 | 2021 | Jonathan Kaufman, Chief Executive Officer | 183.3K | — | — | 730.5K | — | — | 913.8K | 79.94% | ↗ |
| 8 | 2021 | Michael Chancellor, Chief Medical Officer | 101.3K | — | — | 730.5K | — | — | 831.8K | 87.83% | ↗ |
| 9 | 2021 | Douglas Johnston, Chief Financial Officer | 12.0K | — | — | — | — | — | 12.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jonathan Kaufman | Co-Founder, Chairman, Chief Executive Officer, President, Secretary & Treasurer | 233.3K | — |
| Douglas Johnston | Chief Financial Officer | 165.0K | male |
| Janet Okonski | Director of Clinical Operations | — | female |
| Katie Johnston | Controller | — | — |
| Michele Gruber | Director of Operations | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for LIPO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
